Patents Examined by Jane Fan
-
Patent number: 6780882Abstract: There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.Type: GrantFiled: September 30, 2002Date of Patent: August 24, 2004Assignee: The Curators of the University of MissouriInventor: Jeffrey O. Phillips
-
Patent number: 6716859Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: wherein Ar1, Ar2, and R1-R2 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: May 10, 2002Date of Patent: April 6, 2004Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, John Drewe, Han-Zhong Zhang
-
Patent number: 6706736Abstract: Compounds of the formula useful for the treatment of depression such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.Type: GrantFiled: March 3, 2003Date of Patent: March 16, 2004Assignee: WyethInventors: Gary P. Stack, Hong Gao, Elizabeth S. Gildersleeve
-
Patent number: 6699885Abstract: Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.Type: GrantFiled: January 19, 2002Date of Patent: March 2, 2004Assignee: The Curators of the University of MissouriInventor: Jeffrey O. Phillips
-
Patent number: 6696470Abstract: A compound of the formula: and its pharmaceutically effective salts, wherein R1 and R2 are independently selected from the following: (a) hydrogen, halo, R5—, C2-6 alkenyl, C2-6 alkynyl, hydroxy-R5—, R5—O—R5—, or the like; (b) Ar—, Ar—R5—, Ar—C2-6 alkenyl, Ar—C2-6 alkynyl, Ar—O—, Ar—O—R5— or the like; (c) R5—C(O)—, —NO2, cyano, NH2—C(O)—, R5—NH—C(O)—, (R5)2—N—C(O)—, Ar—C(O)— or the like; and (d) R5—C(O)—NH—, Ar—C(O)—NH— or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R5 is optionally halo-substituted C1-6 alkyl; R3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R5—C(O)—, C2-6 alkenyl-C(O)—, C2-6 alkynyl-C(O)—, R5—C(O)—R5—, or theType: GrantFiled: July 30, 2001Date of Patent: February 24, 2004Assignee: Pfizer Inc.Inventors: Akiyoshi Kawai, Makoto Kawai
-
Patent number: 6693118Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.Type: GrantFiled: November 20, 2001Date of Patent: February 17, 2004Assignee: Sanofi-SynthelaboInventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
-
Patent number: 6689889Abstract: The present invention relates to the use of optically active polymers of N-acryloyl-phenylalanine neomenthylamide as such, in crosslinked form and/or in carrier-bonded form as stationary phases for the chromatographic separation of enantiomers of lactones.Type: GrantFiled: January 10, 2001Date of Patent: February 10, 2004Assignee: Bayer AktiengesellschaftInventors: Walter Lange, Rolf Grosser, Burkhard Köhler, Stefan Michel, Bruno Bömer, Uwe Zweering
-
Patent number: 6680338Abstract: Compounds having therapeutic utility are of formula (I) B—X—(CH2)n—CR2R3—CR4R5—COY (I) wherein n=0-1; X is S(O)0-2; Y is OR1 or NHOH; R2 and R4 are independently H or a group (optionally substituted with R10) selected from C1-6 alkyl, C2-6 alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, heterocycloalkyl, C1-6 alkyl-heterocycloalkyl, cycloalkyl and C1-6 alkyl-cycloalkyl; and R1, R3 and R5 are independently H or C1-6 alkyl, provided that not more than two of R2, R3, R4 and R5 are H; or any of CR2R3, CR4R5 and CR2—CR4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R10 or a group (optionally substituted with R10) selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and C1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R6 or R7) bonded through carbon to X, or C1-6 alkyl-heterocycloalkyl (optionally substituted with R6 or R7), or a group (substituted with R6) selected from C1-8 alkylType: GrantFiled: February 6, 2001Date of Patent: January 20, 2004Assignee: Darwin Discovery Ltd.Inventors: John Gary Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson
-
Patent number: 6677455Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: February 14, 2002Date of Patent: January 13, 2004Assignee: AstraZeneca ABInventors: Anders Kronström, Eva Leander, Anders Mattson
-
Patent number: 6673745Abstract: The invention relates to novel compounds of formula I: wherein R, A, B and X have the meaning given in claim 1; and the agronomically acceptable salts or N-oxides thereof, and to herbicidal compositions containing such compounds as active ingredients.Type: GrantFiled: January 12, 2001Date of Patent: January 6, 2004Assignee: BASF AktiengesellschaftInventors: Thomas Maier, Stefan Scheiblich, Helmut S. Baltruschat
-
Patent number: 6673819Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.Type: GrantFiled: December 20, 2001Date of Patent: January 6, 2004Assignee: AstraZeneca ABInventors: Rolf Bergman, Arne Eek, Lars-Inge Olsson, Per Lindberg
-
Patent number: 6670307Abstract: 1,3-Oxazoline and 1,3-thiazoline derivatives, their preparation, and their use as pesticides 1,3-Oxazoline and 1,3-thiazoline derivatives of the formula (I) where the symbols have the following meanings: A is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl or thienyl, E is a single bond, (C1-C4)alkylene, —O—CH2— or —CH2—O—; G is a radical selected from the group consisting of Z is oxygen or sulfur. Compounds of the formula (I) have, in particular, a very good acaricidal and insecticidal action with regard to the spectrum of action and the potency.Type: GrantFiled: June 21, 2001Date of Patent: December 30, 2003Assignee: Hoechst Schering AgrEvo GmbHInventors: Stefan Schnatterer, Manfred Kern, Ulrich Sanft, Christina Mertens
-
Patent number: 6667322Abstract: Compounds of the formula useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.Type: GrantFiled: October 4, 2002Date of Patent: December 23, 2003Assignee: WyethInventors: Jonathan Laird Gross, Richard Eric Mewshaw, Gary Paul Stack
-
Patent number: 6667325Abstract: Substituted pyrazole compounds represented by formula (I), or salts thereof are disclosed, wherein R1 is —CH(OH)—CH(R4)—(A)n—Y, —CH2—CH(R4)—(A)n—Y, —CO—B1—A—Y or the like (wherein A is a lower alkylene; Y is an aryl group which may be substituted, for example, by halogen, or the like; R4 is a hydrogen atom or a lower alkyl group; B1 is —CH(R4)— or —N(R4)—; and n is 0 or 1); R2 is a hydrogen atom, a lower alkyl group which may be substituted by hydroxyl or the like, or an aralkyl group; R3 is a phenyl group which may be substituted by halogen or the like, or a pyridyl group; and Q is a pyridyl or quinolyl group. These substituted pyrazole compounds or their salts have an excellent p38MAP kinase inhibiting effect and are hence useful in the prevention or treatment of tumor necrosis factor &agr;-related diseases, interleukin 1-related diseases, interleukin 6-related diseases or cyclooxygenase II-related diseases.Type: GrantFiled: December 3, 2001Date of Patent: December 23, 2003Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventors: Nobuyoshi Minami, Michitaka Sato, Koichi Hasumi, Norio Yamamoto, Katsuyuki Keino, Teruaki Matsui, Arihiro Kanada, Shuji Ohta, Takahisa Saito, Shuichiro Sato, Akira Asagarasu, Satoshi Doi, Motohiro Kobayashi, Jun Sato, Hajime Asano
-
Patent number: 6664276Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.Type: GrantFiled: September 13, 2002Date of Patent: December 16, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Akira Fujishima, Isao Aoki, Keiji Kamiyama
-
Patent number: 6664277Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.Type: GrantFiled: January 3, 2003Date of Patent: December 16, 2003Assignee: PPD Discovery, Inc.Inventors: Bradley B. Brown, Kenneth S. Rehder, Jon-Paul Strachan, Jeron H. Eaves, Christopher T. Lowden
-
Patent number: 6656948Abstract: Compounds of the following formula: wherein all variables are as defined in the specification. The compounds have cytotoxic properties and can therefore be used in the treatment of malignant tumors.Type: GrantFiled: September 24, 2001Date of Patent: December 2, 2003Assignee: Universidad Complutense de MadridInventors: José Luis Fernandez Puentes, Dolores Garcia Gravalos, Carmen Avendano Lopez, Maria del Mar Blanco Castro, Jose Carlos Menendez Ramos
-
Patent number: 6653481Abstract: Amlodipine and related analogues thereof are prepared by the following general reaction scheme: R1 and R2 each independently represent a C1-C4 alkyl group. The process provides for the formation of compounds of formula (1) in good yield and purity. Further, the compounds of formula (1) can be used as calcium channel blockers or as reference standards or reference markers for checking the purity of amlodipine.Type: GrantFiled: August 27, 2001Date of Patent: November 25, 2003Assignee: Synthon BVInventors: Theodorus H. A. Peters, Franciscus B. G. Benneker, Pavel Slanina, Jiri Bartl
-
Patent number: 6649638Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.Type: GrantFiled: January 3, 2003Date of Patent: November 18, 2003Assignee: PPD Discovery, Inc.Inventors: Bradley B. Brown, Kenneth S. Rehder
-
Patent number: RE38624Abstract: The invention relates to new hydroxyindoles of the Formula, their use as inhibitors of phosphodiesterase 4 and processes for their preparation.Type: GrantFiled: September 19, 2002Date of Patent: October 12, 2004Assignee: Elbion AGInventors: Norbert Hofgen, Ute Egerland, Hildegard Kuss, Degenhard Marx, Stefan Szelenyi, Thomas Kronbach, Emmanuel Polymeropoulos, Sabine Heer